PMID- 30135657
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 9
DP  - 2018
TI  - Lobeglitazone Attenuates Airway Inflammation and Mucus Hypersecretion in a Murine 
      Model of Ovalbumin-Induced Asthma.
PG  - 906
LID - 10.3389/fphar.2018.00906 [doi]
LID - 906
AB  - Lobeglitazone (LB) is a novel agonist of peroxisome proliferator-activated 
      receptor (PPAR)-alpha and gamma that was developed as a drug to treat diabetes mellitus. 
      We explored the ameliorative effects of LB on allergic asthma using a murine 
      model of ovalbumin (OVA)-induced asthma. To boost the immune response of animals, 
      OVA sensitization was performed on days 0 and 14. LB (250 or 500 mug/kg) was 
      administered by oral gavage on days 18 to 23, and the OVA challenge was performed 
      using an ultrasonic nebulizer on days 21 to 23. Plethysmography showed airway 
      hyperresponsiveness (AHR) on day 24. LB treatment effectively decreased 
      inflammatory cell recruitment, T-helper type 2 cytokines in the bronchoalveolar 
      lavage fluid, and immunoglobulin (Ig) E in the serum of the animals with 
      OVA-induced asthma, which was accompanied by a marked reduction in AHR. It also 
      decreased airway inflammation, mucus hypersecretion, phosphorylation of nuclear 
      transcription factor-kappa-B (NF-kappaB), and expression of activating protein (AP)-1 
      and mucin 5AC (MUC5AC). Overall, LB effectively attenuated the pathophysiological 
      changes of asthma and its effects appear related to a reduction in the 
      phosphorylation of NF-kappaB and the expression of AP-1. Thus, our results suggest 
      that LB has a potential to treat allergic asthma.
FAU - Shin, Na-Rae
AU  - Shin NR
AD  - College of Veterinary Medicine BK21 Plus Project Team, Chonnam National 
      University, Gwangju, South Korea.
FAU - Park, Sung-Hyeuk
AU  - Park SH
AD  - College of Veterinary Medicine BK21 Plus Project Team, Chonnam National 
      University, Gwangju, South Korea.
FAU - Ko, Je-Won
AU  - Ko JW
AD  - College of Veterinary Medicine BK21 Plus Project Team, Chonnam National 
      University, Gwangju, South Korea.
FAU - Cho, Young-Kwon
AU  - Cho YK
AD  - College of Health Sciences, Cheongju University, Cheongju, South Korea.
FAU - Lee, In-Chul
AU  - Lee IC
AD  - Natural Product Research Center, Korea Research Institute of Bioscience and 
      Biotechnology, Jeongeup, South Korea.
FAU - Kim, Jong-Choon
AU  - Kim JC
AD  - College of Veterinary Medicine BK21 Plus Project Team, Chonnam National 
      University, Gwangju, South Korea.
FAU - Shin, In-Sik
AU  - Shin IS
AD  - College of Veterinary Medicine BK21 Plus Project Team, Chonnam National 
      University, Gwangju, South Korea.
FAU - Kim, Joong-Sun
AU  - Kim JS
AD  - K-herb Research Center, Korea Institute of Oriental Medicine, Daejeon, South 
      Korea.
LA  - eng
PT  - Journal Article
DEP - 20180808
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC6092601
OTO - NOTNLM
OT  - airway inflammation
OT  - asthma
OT  - lobeglitazone
OT  - mucus hypersecretion
OT  - peroxisome proliferator-activated receptor
EDAT- 2018/08/24 06:00
MHDA- 2018/08/24 06:01
PMCR- 2018/08/08
CRDT- 2018/08/24 06:00
PHST- 2018/05/18 00:00 [received]
PHST- 2018/07/24 00:00 [accepted]
PHST- 2018/08/24 06:00 [entrez]
PHST- 2018/08/24 06:00 [pubmed]
PHST- 2018/08/24 06:01 [medline]
PHST- 2018/08/08 00:00 [pmc-release]
AID - 10.3389/fphar.2018.00906 [doi]
PST - epublish
SO  - Front Pharmacol. 2018 Aug 8;9:906. doi: 10.3389/fphar.2018.00906. eCollection 
      2018.